264 related articles for article (PubMed ID: 25491927)
1. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
Vardigan JD; Cannon CE; Puri V; Dancho M; Koser A; Wittmann M; Kuduk SD; Renger JJ; Uslaner JM
Psychopharmacology (Berl); 2015 Jun; 232(11):1859-66. PubMed ID: 25491927
[TBL] [Abstract][Full Text] [Related]
2. The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys.
Lange HS; Cannon CE; Drott JT; Kuduk SD; Uslaner JM
J Pharmacol Exp Ther; 2015 Dec; 355(3):442-50. PubMed ID: 26446308
[TBL] [Abstract][Full Text] [Related]
3. The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.
Puri V; Wang X; Vardigan JD; Kuduk SD; Uslaner JM
Behav Brain Res; 2015; 287():96-9. PubMed ID: 25800972
[TBL] [Abstract][Full Text] [Related]
4. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque.
Uslaner JM; Eddins D; Puri V; Cannon CE; Sutcliffe J; Chew CS; Pearson M; Vivian JA; Chang RK; Ray WJ; Kuduk SD; Wittmann M
Psychopharmacology (Berl); 2013 Jan; 225(1):21-30. PubMed ID: 22825578
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
6. TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys.
Kurimoto E; Nakashima M; Kimura H; Suzuki M
PLoS One; 2019; 14(3):e0207969. PubMed ID: 30856192
[TBL] [Abstract][Full Text] [Related]
7. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects.
Bymaster FP; Carter PA; Peters SC; Zhang W; Ward JS; Mitch CH; Calligaro DO; Whitesitt CA; DeLapp N; Shannon HE; Rimvall K; Jeppesen L; Sheardown MJ; Fink-Jensen A; Sauerberg P
Brain Res; 1998 Jun; 795(1-2):179-90. PubMed ID: 9622623
[TBL] [Abstract][Full Text] [Related]
8. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
9. M
Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
[TBL] [Abstract][Full Text] [Related]
10. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
11. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
[TBL] [Abstract][Full Text] [Related]
12. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
13. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
[TBL] [Abstract][Full Text] [Related]
14. A novel derivative of xanomeline improves fear cognition in aged mice.
Si W; Zhang X; Niu Y; Yu H; Lei X; Chen H; Cao X
Neurosci Lett; 2010 Apr; 473(2):115-9. PubMed ID: 20178835
[TBL] [Abstract][Full Text] [Related]
15. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
[TBL] [Abstract][Full Text] [Related]
16. Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials.
McArthur RA; Gray J; Schreiber R
Curr Opin Investig Drugs; 2010 Jul; 11(7):740-60. PubMed ID: 20571970
[TBL] [Abstract][Full Text] [Related]
17. Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.
Thomsen M; Fulton BS; Caine SB
Psychopharmacology (Berl); 2014 Feb; 231(3):469-79. PubMed ID: 23995301
[TBL] [Abstract][Full Text] [Related]
18. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
19. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
[TBL] [Abstract][Full Text] [Related]
20. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
Jakubík J; El-Fakahany EE; Dolezal V
Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
